Consequently, IL-22 and IL-22BP coregulate antimicrobial immunity against S. pneumoniae, suggesting that IL-22RA2 may be an effective target for the treatment of pneumococcal pneumonia [55]. Here, IL22RA2 is linked to pneumococcal pneumonia.